Maha Katabi is a General Partner of Sofinnova Investments. She is an experienced investor with over two decades of managing public and private biotech companies through bull and bear markets. She is currently a board member of Marea, Quanta, Star, and Vera (VERA). Most recently Maha was a board member of Aiolos (acquired by GSK) and RayzeBio (RYZB: acquired by BMS), in addition to Amplyx (acquired by Pfizer), Gyroscope (acquired by Novartis) and Northsea.
Prior to joining Sofinnova in 2019, Maha was a Partner at Sectoral Asset Management. There, she formed and led a dedicated team to manage investments in private companies and was a Portfolio Manager for a family of funds investing in small cap healthcare companies. Maha co-invested with Sofinnova in multiple companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), and Trius Therapeutics (TSRX-acquired by Cubist). Earlier in her career, she worked as an associate and principal investing in seed and early stage biotech at T2C2/Bio and Ventures West.
Fierce Pharma named Maha one of 2023’s Fiercest Women in Life Sciences. Maha serves as an advisor to amplifyHERscience, a Yale Ventures initiative. She is Board Chair of Exactis Innovation, a not for profit research network for precision oncology operating a data analytics platform to provide real world evidence data to clinical researchers and payors.
Maha received a Ph.D. in Pharmacology and a B.Sc. in Biology at McGill University and was awarded a Cancer Research Society scholarship. She is a CFA charterholder.
